MGX — Metagenomi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1785279 ·
Last close
$0.63
Market Cap
$23.86M
52W High
$1.87
52W Low
$0.60
ADV30
183,198
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 2,184,000 | — | -22,226,000 | -21,126,000 | 157,388,000 | 36,107,000 | 64,200,000 |
| Jun 2026 | -257,000 | — | -28,773,000 | -27,482,000 | 173,701,000 | 39,028,000 | 61,134,000 |
| Mar 2026 | 1,248,000 | — | -24,587,000 | -23,059,000 | 196,953,000 | 25,306,000 | 59,168,000 |
| Dec 2025 | 3,911,000 | — | -24,367,000 | -22,528,000 | 221,103,000 | 41,722,000 | 62,507,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-83,317,000
Investing CF
$85,682,000
Financing CF
$114,000
CapEx
$-309,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-382,537,000
Inventory
—
Receivables
$0
ST Investments
$65,567,000
EBIT TTM
$-99,953,000
Pretax Income TTM
$-94,151,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,086,000
EBITDA
$-94,859,000
Free Cash Flow
$-47,260,624
Enterprise Value
$-39,311,820
Total Cash
$101,674,000
Total Debt
$36,212,000
Shares Out
37,805,669
Trailing EPS
$-2.50
Book Value
$2.46
ROE
-69.4%
ROA
-30.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,210,000 | -96,013,000 | -87,868,000 | 221,103,000 | 62,507,000 | 158,596,000 | -88,892,000 |
| Dec 2024 | 52,295,000 | -88,901,000 | -78,058,000 | 324,599,000 | 89,742,000 | 234,857,000 | -109,073,000 |
| Dec 2023 | 44,756,000 | -78,492,000 | -68,255,000 | 364,842,000 | 500,426,000 | -135,584,000 | -91,409,000 |
| Dec 2022 | 17,200,000 | -44,640,000 | -43,593,000 | 414,486,000 | 488,914,000 | -74,428,000 | 29,724,000 |
TTM Snapshot
Revenues TTM
$15,074,000
NetIncome TTM
$-93,462,000
OpCashFlow TTM
—
Assets (Latest)
$173,701,000
Forward EPS
$-1.83
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZIVO | Zivo Bioscience, Inc. | $23.18M | $5.50 | — |
| EVAX | Evaxion A/S | $25.08M | $2.78 | — |
| LONA | LeonaBio, Inc. | $26.00M | $2.76 | — |
| PTHS | Pelthos Therapeutics Inc. | $26.89M | $6.84 | — |
| SAEN | Genenta Science S.p.A. | $27.82M | $0.58 | — |
News headlines (Yahoo Finance, 1h cache)
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
2026-11-11 13:00 · Yahoo
Metagenomi Therapeutics: Q3 Earnings Snapshot
2026-11-10 22:14 · Yahoo
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
2026-11-10 21:05 · Yahoo
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
2026-11-04 14:25 · Yahoo
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
2026-10-13 12:00 · Yahoo
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
2026-09-01 12:00 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 21:55 · Yahoo
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
2026-08-10 20:05 · Yahoo
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-05-11 20:05 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-12 00:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.